and effects: Lumbar disc herniation by prolapse of the posterior longitudinal ligament
for which sufficient improvement cannot be obtained through conservative treatment Usage and dosage: For adults, 1.25 units of condoliase are administered by a single injection in the intervertebral disc that is the source of the symptoms.
NHI drug: 1 bottle containing 1.25units
New Drug Application approval date: March 23, 2018
Date of listing in the National Health Insurance drug price list: May 22, 2018
Launch date: August 2018 (planned)
Marketing authorization holder: Seikagaku Corporation
Distributor: Kaken Pharmaceutical Co. Ltd.
Mechanism of action: It is expected that condoliase degrades chondroitin sulfate, chondroitin, and hyaluronic acid and also improves the clinical manifestations of herniation by lowering the internal pressure of the intervertebral disc due to dissolving the glycosaminoglycans* within the nucleus pulposus of the intervertebral disc, and lowering the water-holding capacity of the nucleus pulposus.
* Glycosaminoglycans(GAG): A major component of complex carbohydrates.Chondroitin sulfate and hyaluronic acid etc.
Lumbar disc herniation is the partial protrusion of the nucleus pulposus at the core ofeach intervertebral disc or the annulus fibrosus, the disc's outer layer.The resulting pressure on the spinal nerve root causes pain and numbness.
Current treatments are generally categorized into conservative treatments for temporalpain relief (rest and pharmaceutical methods such as NSAIDs)and surgical treatments.
As this Agent specifically degrades GAGs in the nucleus pulposus, resulting in decrease in the pressure on the nerve root, it is positioned as an innovative treatment of lumbar disc herniation. |
